

REVIEW

Open Access



# Compartmentalization and transporter engineering strategies for terpenoid synthesis

Ke Jin<sup>1,2</sup>, Hongzhi Xia<sup>3</sup>, Yanfeng Liu<sup>1,2</sup>, Jianghua Li<sup>1,2</sup>, Guocheng Du<sup>1,2</sup>, Xueqin Lv<sup>1,2\*</sup> and Long Liu<sup>1,2\*</sup>

## Abstract

Microbial cell factories for terpenoid synthesis form a less expensive and more environment-friendly approach than chemical synthesis and extraction, and are thus being regarded as mainstream research recently. Organelle compartmentalization for terpenoid synthesis has received much attention from researchers owing to the diverse physicochemical characteristics of organelles. In this review, we first systematically summarized various compartmentalization strategies utilized in terpenoid production, mainly plant terpenoids, which can provide catalytic reactions with sufficient intermediates and a suitable environment, while bypassing competing metabolic pathways. In addition, because of the limited storage capacity of cells, strategies used for the expansion of specific organelle membranes were discussed. Next, transporter engineering strategies to overcome the cytotoxic effects of terpenoid accumulation were analyzed. Finally, we discussed the future perspectives of compartmentalization and transporter engineering strategies, with the hope of providing theoretical guidance for designing and constructing cell factories for the purpose of terpenoid production.

**Keywords:** Terpenoids, Compartmentalization, Transporter, Metabolic engineering

## Introduction

Terpenoids are the largest and most diverse class of natural products, with over 80,000 different structures identified in plants, microorganisms, and marine organisms [1, 2]. All terpenoids are derived from the isoprene (C<sub>5</sub>) unit isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP). Terpenoids are classified as monoterpenes (C<sub>10</sub>), sesquiterpenes (C<sub>15</sub>), diterpenes (C<sub>20</sub>), triterpenes (C<sub>30</sub>), tetraterpenes (C<sub>40</sub>), and polyterpenes (C > 40) based on the number of isoprene units [3]. For instance, menthol (monoterpene) is one of the most important flavoring additives [4], artemisinic acid (sesquiterpene) is a well-known antimalarial drug [5], paclitaxel (diterpene) can be used as an anticancer drug [6], ginsenoside (triterpene) can inhibit the growth

of tumor cells [7], and lycopene (tetraterpene) has a high antioxidant potential [8]. Terpenoids have been extensively applied in pharmaceutical and industrial sectors for decades owing to their diverse biological activities and high bioavailability, thereby resulting in their large market demand.

The two primary methods for obtaining plant terpenoids are plant extraction and chemical synthesis [9]. However, because the terpenoid concentration is low in plants and other problems, such as long cycles and environmental dependence on plant culture, scaling up the production of plant extraction is challenging [10, 11]. While the multiple stereocenters of most terpenoids complicate product synthesis and separation in the traditional chemical synthesis [12], this approach is also accompanied by the use of several organic reagents, which can exert a strain on the environment. To avoid the aforementioned problems, the development of microbial cell factories for efficient terpenoid synthesis has emerged as an important research direction for the sustainable production of terpenoids because microbial

\*Correspondence: lvxueqin@jiangnan.edu.cn; longliu@jiangnan.edu.cn

<sup>1</sup> Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China  
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

cell factories provide benefits of low cost, environmental friendliness, and high production efficiency [13, 14].

Terpenoid production by fermentation of microbial chassis has achieved remarkable results in recent years because of the rapid development of metabolic engineering and synthetic biology [13, 15]. Paddon et al., for instance, developed a strain of *Saccharomyces cerevisiae* for high-yielding biological production of artemisinic acid, with a fermentation titer of 25 g/L, which met commercialization, by providing the complete biosynthetic pathway and optimizing the fermentation process [16]. Wang et al. successfully constructed a chassis cell with a high yield of ginsenoside aglycone protopanaxadiol through modular engineering of the mevalonic acid (MVA) pathway and optimizing the P450 enzyme expression levels. The production of ginsenoside Rh2 was found to substantially increased, with 179.3 mg/L in shake flasks and 2.25 g/L in 10-L fed-batch fermentation, when combined with the regulation strategy of increasing glycosylation modification [11]. Currently, some researchers have suggested that in addition to enhancing the synthesis pathway [17, 18], rewriting the central carbon metabolism [19], balancing the competition pathway [20, 21], and heterologously expressing cytochrome P450 enzymes may be effective ways for terpenoid synthesis [22, 23]. However, apart from the traditional metabolic strategies, researchers now found that making full use of organelles in microorganisms may provide new insights to further improve the yield of terpenoid, such as increasing the storage capacity [24, 25].

This review focuses on the strategies for improving storage capacity and compartmentalization regulation for plant terpenoid synthesis using microbial cell factories. The physiological properties of various organelles, in addition to their benefits and drawbacks for compartmentalization, were thoroughly analyzed. The efflux pumps or secretion strategies to export terpenoids were also reported. Finally, the future perspectives and challenges associated with compartmentalization and transporter engineering strategies were thoroughly discussed.

### Compartmentalization strategies for effective synthesis of terpenoids

Eukaryotes can synthesize and store terpenoids via a complete and orderly production line depending on the various organelles and membrane structures they possess such as the endoplasmic reticulum (ER), Golgi complex, lipid droplets (LDs), peroxisomes, mitochondria, and plasma membrane (PM) [26]. However, terpenoid accumulation has the potential to cause cell toxicity, whereas the compartmentalization strategy can not only improve the catalytic efficiency of enzymes but also avoid the harmful effects of toxic substances on cells [26–28]. As

a result, studies are being conducted for immobilizing the enzymes required for terpenoid synthesis in various organelle compartments.


### ER engineering

Other than nucleic acids, ER serves as the base for the synthesis of a series of important substances in cells [29]. ER is speculated to have a crucial role in terpenoid synthesis either in the form of enzyme synthesis and processing or specific ER localization of some enzymes such as key enzymes in the MVA pathway and cytochrome P450 [30]. Thus, ER engineering is a focus of research to improve the efficiency of terpenoid synthesis. Recently, ER engineering has primarily focused on increasing the ER size (Fig. 1a) [31].

After deleting the phosphatidic acid phosphatase-encoding *PAH1* in *S. cerevisiae* and *Yarrowia lipolytica*, a dramatic expansion in ER was observed (Table 1) [32, 33]. The massive proliferation of ER membranes is frequently followed by improvement in their ability to synthesize and fold protein, as well as an increase in protein accumulation levels [34, 35]. For instance, the *S. cerevisiae* strain with disrupted *PAH1* expression could accumulate more *Glycyrrhiza glabra*  $\beta$ -amyrin synthase (GgbAS), and the accumulation of triterpenoids, including oleanane-type saponin  $\beta$ -amyrin, and medicagenic-28-O-glucoside, respectively increased by 8-fold and 16-fold in the  $\Delta$ *pah1* strain compared with the control strain [33]. Notably, *PAH1* knockout tends to reduce the number of LDs [36], and some key enzymes, such as the oxidosqualene cyclases (OSCs), usually require to be positioned in LDs so that they may function normally. As a result, the trade-off between ER and LDs must be considered [37, 38]. Overexpression of the key ER size regulatory factor *INO2* causes ER expansion and a dramatic boost in the yield of squalene and ginsenoside by 128 times and 7 times, respectively [34, 35].

### LD engineering

LDs are ER-derived organelles that serve as the primary storage sites for neutral lipids in cells. The LD core is composed of neutral lipids, primarily including triacylglycerols (TAGs) and sterol esters (SEs) [39]. A single-layer phospholipid membrane containing various proteins involved in the biogenesis and function of the organelle surrounds the core [40]. The co-accumulation and co-occurrence of terpenoids and neutral lipids in LDs not only promote further elucidation of the isolation mechanism of the bioactive defense compounds intracellularly, but also provides an opportunity for metabolic engineering and synthetic biology to engineer the high-yield production and storage of terpenoids in the cells with LDs [41–43].



**Fig. 1** a ER, b LD, c peroxisome and d mitochondrion used for compartmentalization strategies. G3P: glycerol-3-phosphate; PA: phosphatidic acid; DAG: diacylglycerol; TAG: triacylglycerol; SE: sterol esters; PLN1: perilipin; PAH1: phosphatidic acid phosphatase; DGA1: diacylglycerol acyltransferase

When enzymes and their substrates are compartmentalized, the transformation ability of engineering strains may be extremely low [44]. Anchoring the key enzymes of distinct biosynthetic steps on the surface or inside LDs promotes increased local concentrations of enzymes and hydrophobic substrates, which result in the efficient production of terpenoids. Indeed, the ectopic expression of enzymes in LDs is inextricably linked to the specific localization proteins or corresponding localization peptides, such as PLN1, which is involved in the formation and stability of LDs [45]. The conversion of dammarenediol-II into protopanaxadiol by a normal ER-localized cytochrome P450 enzyme (protopanaxadiol synthase) is a key step in the synthesis pathway of ginsenoside. Given that LDs are the storage organelles of dammarenediol-II, Shi et al. directed protopanaxadiol synthase to LDs using

yeast PLN1 protein as the guide protein to obtain a chassis strain. The production of ginsenoside compound K in engineering a chassis strain was 21.8 mg/L/OD, which was nearly 4.4-fold higher than that using the native ER expression strategy [44, 46].

Another key factor in enhancing the ability of cells to synthesize terpenoids is the storage capacity of LDs. Cytosolic LDs are dynamic organelles that vary in size and morphology, and some small LDs can merge to form larger LDs. As the primary factor for TAG synthesis in the oleaginous yeast *Y. lipolytica*, the expression of diacylglycerol acyltransferases (DGATs) influences the size, quantity, and even distribution of LDs [43]. Overexpression of the DGAT gene *YIDGA1* causes *Y. lipolytica* cells to produce smaller but more numerous LDs, whereas the overexpression of *YIDGA2* (also a DGAT gene) results in

**Table 1** Terpenoid production using different organelle compartmentalization strategies

Organelle	Yeast species	Products	Titer or yield	Major engineering strategies	References	
Endoplasmic reticulum	<i>S. cerevisiae</i>	β-amyrin	N.A.	Knock out <i>PAH1</i>	[33]	
		Aedicagenic-28-O-glucoside	27.1 mg/L	Knock out <i>PAH1</i>	[33]	
		Artemisinic acid	N.A.	Knock out <i>PAH1</i>	[33]	
		Squalene	634 mg/L	Overexpression of <i>INO2</i>	[35]	
		Ginsenoside	12.1 mg/L	Overexpression of <i>INO2</i>	[35]	
Lipid droplet	<i>Y. Lipolytica</i>	Lycopene	16 mg/g	Strengthen the isoprenoid biosynthesis pathway and block the β-oxidation pathway	[47]	
		Squalene	731.18 mg/L	Co-overexpression of <i>tHMG1</i> and <i>DGA1</i>	[53]	
	<i>S. cerevisiae</i>	Squalene	445.6 mg/L	Co-overexpression of <i>tHMG1</i> and <i>DGA1</i>	[54]	
		Lycopene	2.37 g/L (73.3 mg/g)	Strengthen the TAG pathway and modulate TAG fatty acyl composition	[49]	
		Ginsenoside	5 g/L	Target protopanaxadiol synthase to LDs and strengthen the TAG pathway	[44]	
Peroxisome	<i>P. pastoris</i>	Lycopene	73.9 mg/L	Target heterologous carotenogenic enzymes to peroxisomes	[74]	
		α-humulene	3.2 g/L	Introduce the α-humulene synthesis pathway to peroxisomes	[77]	
		Squalene	11 g/L	Hybridization of the cytoplasm- and peroxisome-engineered strain	[63]	
	<i>S. cerevisiae</i>	Geraniol	2.75 mg/L	Deletion of <i>PEX30</i> and <i>PEX32</i> and introduce the geraniol synthesis pathway into peroxisomes	[72]	
			5.5 g/L	Introduce a complete MVA pathway in peroxisomes	[75]	
		(R)-(+)-limonene	2.6 g/L	Introduce a complete MVA pathway in peroxisomes	[75]	
		Protopanaxadiol	N.A.	Knock out <i>PEX11</i> , <i>PEX34</i> , and <i>ATG36</i>	[73]	
	Mitochondrion	<i>S. cerevisiae</i>	α-humulene	1726.78 mg/L	Introduce the α-humulene biosynthesis pathway into peroxisomes and block the expression of <i>ERG9</i>	[76]
			β-Amyrin	2.6 g/L	Introduce the MVA pathway into peroxisomes	[78]
			Valencene	1.5 mg/L	Co-overexpression of <i>tHMG1</i> , mitochondrion-targeted heterologous FDP synthase and amorphadiene synthase	[84]
Amorphadiene			20 mg/L	Co-overexpression of <i>tHMG1</i> , mitochondrion-targeted heterologous FDP synthase and amorphadiene synthase	[84]	
Amorpha-4,11-diene			427 mg/L	Introduce the amorpha-4,11-diene biosynthesis pathway to mitochondria	[86]	
Linalool			21 mg/L	Dual mevalonate pathways in mitochondria and cytoplasm	[88]	
Geraniol			43.3 mg/L	Introduce the geraniol biosynthetic pathway into mitochondria	[89]	
Plasma membrane	<i>S. cerevisiae</i>	Patchoulol	19.24 mg/L	Introduce the DMAPP pathway into mitochondria	[90]	
		Isoprene	2527 mg/L	Introduce the complete MVA pathway together with isoprene synthase (ISPS) into mitochondria	[91]	
	<i>E. coli</i>		11.9 g/L	Dual regulation of cytoplasmic and mitochondrial acetyl-CoA utilization	[92]	
		β-Ionone	184 mg/L (32 mg/g)	Target the β-carotene cleavage dioxygenase to the membrane	[95]	
	Astaxanthin	N.A.	Target <i>CrtW</i> and <i>CrtZ</i> to the membrane via a GlpF protein	[94]		



**Table 1** (continued)

Organelle	Yeast species	Products	Titer or yield	Major engineering strategies	References
		Squalene	612 mg/L	Overexpression of <i>TSR</i> to expand membrane volume	[93]
		$\beta$ -carotene	44.2 mg/g DCW	Overexpression of <i>ALMGS</i> and <i>PLSB/PLSC</i> to increase membrane surface area and enhance membrane synthesis	[24]

the production of larger LDs [39]. Furthermore, deletion of *GUT2* and *POX1–POX6* in *Y. lipolytica* increases the size of LDs, because the deletion of *GUT2* can prevent the reduction of the glycerol-3-phosphate pool, whereas deletion of the latter cuts peroxisomal  $\beta$ -oxidation short (Fig. 1b) [47].

Using lycopene synthesis as an example, Matthäus et al. found that increased LDs formation by *Y. lipolytica* could improve the storage capacity of cells for lycopene and subsequently improve lycopene synthesis, with a yield of 16 mg/g cell dry weight (CDW) [47]. Similarly, by overexpressing diacylglycerol acyltransferase (*DGAI*) to increase the intracellular storage capacity of *S. cerevisiae*, along with increased expression of key genes of the MVA pathway, the fermentation yield of  $\alpha$ -amyrin in the engineering strain was found to be 106 times higher than that in the control strain [48]. Furthermore, the lycopene yield in *S. cerevisiae* strains overexpressing fatty acid desaturase (*OLE1*) and knocking out seipin (*FLD1*), which regulates the size of LDs, reached 70.5 mg/g CDW, which was 25% higher than that of the original high-yield strain [49].

The hydrophobic environment within LDs makes them excellent storage organelles for terpenoids. As a result, LD compartmentalization has recently become the focus of research for improving the yield of terpenoids [38]. As more clarity is gained on the mechanism underlying LD formation, mining other ways to manipulate the number and size of LDs other than enhancing the TAG pathway can potentially provide a new basis for further improvement of the terpenoid yield [50–54].

### Peroxisome engineering

Peroxisomes are the primary organelles enclosed within a single bilayer membrane, which have an important role in cell detoxification. Peroxisomes can be generated using two pathways: “division” and “regeneration.” In case of division, mature peroxisomes divide to produce offspring peroxisomes [55–57]. Regeneration is a relatively complex process that involves three successive processes: budding from the ER membrane to form precursor membrane vesicles, forming the prototype of the peroxidase body, and finally generating a mature peroxidase body [56]. Peroxisomes have long been associated with fatty acid catabolism, particularly in yeast, because they are

the only sites where fatty acid  $\beta$ -oxidation occurs, which implies that this organelle can accommodate hydrophobic chemicals [58–61]. Peroxisomes can also simultaneously produce farnesyl diphosphate (FPP), an important metabolic precursor in isoprenoid biosynthesis, which further suggests that peroxisomes are central to terpenoid synthesis [62].

Peroxisomes can be used as subcellular factories or storage depots for various terpenoids, particularly those in non-oleophilic yeasts, such as *S. cerevisiae*, which lack lipid storage space [55, 63–65]. Peroxisome size and number, similar to LDs, can be regulated in a dynamic manner to optimize terpenoid production [66–68]. Modulating the expression of peroxin (PEX) and autophagy (ATG) protein family members, which are responsible for peroxisome biogenesis and pexophagy, respectively in *S. cerevisiae*, may increase the peroxisome proliferation (Fig. 1c) [56, 57, 69–71]. The co-knockout of *PEX30* and *PEX31*, for instance, resulted in a 5.6-fold increase in the peroxisome number [72]. Thus, by improving the tolerance of yeast cells to geraniol and compartmentalizing the geraniol-producing enzymes into peroxisomes, the titer of geraniol was found to increase by 80% [72]. Similar results were also observed in the protopanaxadiol-producing strain [73]. Furthermore, using peroxisome targeting sequence 1, the non-carotenogenic yeast *Pichia pastoris* was able to produce 73.9 mg/L lycopene by targeting heterologous carotene-producing enzymes to peroxisomes [74]. Similar strategies have been used in the biosynthesis of various monoterpenes [75], sesquiterpenes, including  $\alpha$ -humulene [76, 77], and triterpenoids, including squalene [63],  $\beta$ -amyrin [78], and protopanaxadiol [73].

### Mitochondrion engineering

Unlike monolayers of LDs and peroxisomes, mitochondria are semi-autonomous organelles surrounded by two layers of membrane, with their inner membrane forming multiple ridges, which can gradually release energy through respiration to meet the requirements of various cell activities. Because acetyl-CoA is an important precursor for terpenoid synthesis, mitochondria have a much higher acetyl-CoA content (nearly 20–30 times higher) than the cytoplasm, which increases the

feasibility of mitochondrial compartmentalization for terpenoid synthesis [79, 80]. However, IPP and DMAPP, which are synthesized from acetyl-CoA via the MVA pathway, are ATP analogs that are strong inhibitors of the mitochondrial respiratory chain. As a result, when the MVA pathway is integrated into the mitochondria, care should be taken to effectively avoid cytotoxicity [81–83].

Rational utilization of FPP pool is a possible strategy for enhancing the production of exogenous terpenoids, and the presence of FPP pools is another advantage of yeast mitochondria [84]. Heterologous FPP synthase and valencene or amorphadiene synthase were targeted into mitochondria using mitochondrial targeting signals (MTSs) and expressed in the *S. cerevisiae* strain with a truncated and deregulated HMG1, resulting in an 8- and 20-fold increase in the production of valencene and amorphadiene, respectively [84]. The selectivity and applicability of MTSs are frequently associated with the range of mitochondrial compartmentalization applications. At present, the most commonly utilized MTS is the pre-sequence of yeast cytochrome c oxidase subunit IV, which can direct various enzymes into the mitochondrial matrix, both in vitro and in vivo [85]. Of note, once the enzyme has been appropriately transposed into mitochondria, the MTS can be cleaved to avoid the effect of fusion expression on enzyme activity (Fig. 1d) [84, 86].


Mining and screening of more efficient MTSs has been conducted to expand the application of mitochondrial compartmentalization engineering for multigene biosynthetic pathways. Based on the mitochondrial proteome, 6 MTSs were screened for the co-localization of  $\alpha$ -santalene synthesis pathway, which consists of 10

expression cassettes capable of converting acetyl-CoA to  $\alpha$ -santalene, and the results showed that the production of  $\alpha$ -santalene increased by 3.7 times in comparison with the control strain [87]. Indeed, as a promising sub-cellular organelle for compartmentalization engineering, mitochondria merit further investigation by researchers [88–92].

### PM engineering

In addition to other organelles with membrane structures, the PM composed of phospholipid bilayers has piqued the interest of those focused on terpenoid research owing to its ability to store lipophilic molecules. PM engineering has received much attention particularly in the case of prokaryotic microorganisms that lack organelles. The combination of engineering membrane morphology and improving the membrane synthesis pathway could result in a 2.9-fold increase in  $\beta$ -carotene production in *Escherichia coli* [24]. Similarly, overexpression of the serine chemoreceptor Tsr in *E. coli* to wrinkle the inner membrane inward (also can expand the cell membrane) considerably increases the production of squalene synthesis, which is nearly 2.25 times that of the control strain (Fig. 2) [93]. Furthermore, localizing the enzymes close to their substrates within the PM can further improve catalytic efficiency. For instance, using membrane-anchoring peptides or proteins fused to  $\beta$ -carotene cleavage dioxygenase can increase the production of  $\beta$ -ionone [94, 95].

However, excessive hydrophobic molecules in the PM would reduce fluidity and stiffen the cell membrane, thereby causing cellular stress [43, 96, 97]. Increasing the



**Fig. 2** Schematic representation of membrane engineering strategies using *E. coli* as an example. The overexpression of membrane-bending proteins and the enhancement of membrane lipids will lead to membrane expansion for more terpenoid storage. G3P: glycerol-3-phosphate; Diacylglycerol-3P: diacylglycerol-3-phosphate; Tsr: chemotaxis receptor protein; PlsB: glycerol-3-phosphate acyltransferase; PlsC: 1-acylglycerol- phosphate acyltransferase

proportion of unsaturated fatty acids in the PM could be a breakthrough in resolving this problem [98, 99].


**Transport system engineering strategies for effective synthesis of terpenoids**

Higher titers may still be difficult to achieve if continuous terpenoid accumulation is noted in cells because of the limited storage capacity and their toxicity to organelles, proteins, DNA, and other biological processes [100, 101]. As a result, engineering efflux pumps to export terpenoids and thus reduce terpenoid cytotoxicity may be a promising solution [102, 103]. This would simultaneously assist in the recovery of the target products [104]. As typical efflux pumps, most ATP-binding cassette (ABC) transporters in the PM can identify and transport hydrophobic compounds [105–107].

Terpenoids and ABC transporters are correlated because they are both hydrophobic compounds. ABC transporter expression levels are higher in the strains that can efficiently synthesize terpenoids [108–110]. When ABC transporters are overexpressed, the synthesis of some terpenoids increases. For instance,

overexpression of ABC transporter SNQ2 resulted in a 4.04-fold and a 1.33-fold increase in  $\beta$ -carotene secretion and intracellular production, respectively [111]. Moreover, increasing ATP supply or improving membrane fluidity can further increase the production of  $\beta$ -carotene, which is likely because ABC transporters are a class of membrane proteins driven by ATP (Fig. 3a) [112].

Besides a natural protein-based transport system, a novel artificial transport system based on membrane lipids, such as the outer membrane vesicles of *E. coli*, has initially been beneficial in terms of contributing to carrying and transporting terpenoids [113]. The amount of  $\beta$ -carotene secreted by the recombinant *E. coli* strain increased 53 times by promoting the formation of outer membrane vesicles and strengthening the synthesis of phosphatidylethanolamine to compensate for the loss of cell membrane components (caused by the formation of outer membrane vesicles), which indicated that this strategy provides a new direction for the extracellular transport of terpenoids (Fig. 3b) [113].



**Fig. 3** Schematic representation of transport system engineering strategies using *S. cerevisiae* and *E. coli* as an example. **a** Using ABC transporters in *S. cerevisiae* for terpenoid secretion. **b** Engineering *E. coli* cells to produce more outer membrane vesicles by reducing the crosslinks between the inner and outer membrane, and enhancing certain membrane components




## Conclusion and perspectives

Rationally dividing the terpenoid synthesis pathway by anchoring key enzymes to appropriate organelles can increase the concentration of key enzymes and intermediates, which boosts the efficiency of compartmentalized pathway. Although the endomembrane system of certain eukaryotes has long been studied, new phenomena that provide a better insight into this system have emerged [114]. The interrelationships between organelles also deserve further investigation [115]. Simultaneously, additional research has provided a new theoretical basis for compartmentalization. For instance, the discovery of some dual-localization targeting signals may provide additional ideas and methods for enzyme localization (Fig. 4a) [84, 116–118]. As a result, the application of compartmentalization in terpenoid production remains a viable option. Another bottleneck that needs to be broken to increase terpenoid production is the limited storage capacity. However, it is unclear whether the expansion of organelle membranes will result in disorder between organelles or a stress response [119]. Apart from intracellular compartmentalization, taking advantage of constructing and optimizing the expression system and pathway module in parallel, intercellular

compartmentalization can make full use of different biochemical characterizations of hosts and has also been applied in plant terpenoid production recently, such as oxygenated taxanes and strigolactones [120, 121]. Notably, this strategy requires that intermediate metabolites can cross cell membrane. Also, the difference in the doubling time of different hosts makes it particularly important to optimize culture conditions to synthesize more target products. Intercellular compartmentalization provides a promising strategy for complex plant terpenoids, especially when more functional plant-derived proteins are needed to be expressed.

While studies are now focusing more on using ABC transporters to secrete terpenoids to eliminate the toxicity caused by terpenoid accumulation, research that has focused on the mechanism underlying the transportation process is scarce. By analyzing the dynamic process of transportation using methods such as AlphaFold and molecular dynamics simulation, rational protein modification of transporters with poor substrate specificity can most likely be conducted to further improve terpenoid yield (Fig. 4b) [122]. Notably, the synthesis of terpenoids certainly passes through various organelles, such as ER, Golgi LD, and so on. To promote extracellular secretion,





further enhancement of intracellular transportation can theoretically improve terpenoid synthesis to a considerable extent [123]. However, research on accelerating intracellular transportation is still in its infancy and more organelle transporters should be mined (Fig. 4c) [52].

#### Abbreviations

ABC: ATP-binding cassette; CDW: Cell dry weight; DGAT: Diacylglycerol acyl-transferases; DMAPP: Dimethylallyl diphosphate; ER: Endoplasmic reticulum; FPP: Farnesyl diphosphate; GgbAS: Glycyrrhiza glabra  $\beta$ -amyryn synthase; IPP: Isopentenyl diphosphate; LD: Lipid droplet; MTS: Mitochondrial targeting signals; MVA: Mevalonic acid; OSC: Oxidosqualene cyclase; PM: Plasma membrane; SE: Sterol ester; TAG: Triacylglycerol.

#### Acknowledgements

Not applicable.

#### Author contributions

KJ and HX completed the collection and analysis of relevant literatures and the writing of the first draft. KJ and XL revised the manuscript. KJ, XL and LL designed the manuscript. YL, JL and GD assisted in collecting data and monitor the manuscripts. All authors contributed to the manuscript. All authors read and approved the final manuscript.

#### Funding

The research has been funded by the National Natural Science Foundation of China (Grant No. 32021005), the National Key R&D Program of China (Grant No. 2018YFA0900300) and the Fundamental Research Funds for the Central Universities (JUSRP52019A, JUSRP121010, JUSRP221013).

#### Availability of data and materials

Not applicable.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China. <sup>2</sup>Science Center for Future Foods, Jiangnan University, Wuxi 214122, China. <sup>3</sup>Richen Bioengineering Co., Ltd, Nantong 226000, China.

Received: 3 April 2022 Accepted: 12 May 2022

Published online: 23 May 2022

#### References

- Pemberton TA, Chen M, Harris GG, Chou WK, Duan L, Köksal M, et al. Exploring the influence of domain architecture on the catalytic function of diterpene synthases. *Biochemistry*. 2017;56(14):2010–23.
- Vickers CE, Sabri S. Isoprene. *Adv Biochem Eng Biotechnol*. 2015;148:289–317.
- Chandran SS, Kealey JT, Reeves CD. Microbial production of isoprenoids. *Process Biochem*. 2011;46(9):1703–10.
- Kamatou GP, Vermaak I, Viljoen AM, Lawrence BM. Menthol: a simple monoterpene with remarkable biological properties. *Phytochemistry*. 2013;96:15–25.
- Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. *Nature*. 2006;440(7086):940–3.
- Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel produgs: toward smarter delivery of anticancer agents. *J Med Chem*. 2006;49(25):7253–69.
- Kim TJ, Kim HJ, Kang M, Cho JH, Kim YG, Lee SM, et al. Ginsenoside F2 induces cellular toxicity to glioblastoma through the impairment of mitochondrial function. *Phytomedicine*. 2021;83:153483.
- Kim TJ, Kim HJ, Kang M, Cho JH, Kim YG, Lee SM, et al. Can lycopene be considered an effective protection against cardiovascular disease? *Food Chem*. 2018;245:1148–53.
- Quilez del Moral JF, Pérez Á, Barrero AF. Chemical synthesis of terpenoids with participation of cyclizations plus rearrangements of carbocations: a current overview. *Phytochem. Rev*. 2020;19:559–76.
- Zebec Z, Wilkes J, Jervis AJ, Scrutton NS, Takano E, Breitling R. Towards synthesis of monoterpenes and derivatives using synthetic biology. *Curr Opin Chem Biol*. 2016;34:37–43.
- Wang P, Wei W, Ye W, Li X, Zhao W, Yang C, et al. Synthesizing ginsenoside Rh2 in *Saccharomyces cerevisiae* cell factory at high-efficiency. *Cell Discov*. 2019;5:5.
- Hegazy MF, Elshamy AI, Mohamed TA, Hussien TA, Helaly SE, Abdel-Azim NS, et al. Terpenoid bio-transformations and applications via cell/organ cultures: a systematic review. *Crit Rev Biotechnol*. 2020;40(1):64–82.
- Gao R, Falkeborg M, Xu X, Guo Z. Production of sophorolipids with enhanced volumetric productivity by means of high cell density fermentation. *Appl Microbiol Biotechnol*. 2013;97(3):1103–11.
- Mischko W, et al. Modular biomanufacturing for a sustainable production of terpenoid-based insect deterrents. *Green Chem*. 2018;20:2637–50.
- Xu P, Bhan N, Koffas MA. Engineering plant metabolism into microbes: from systems biology to synthetic biology. *Curr Opin Biotechnol*. 2013;24(2):291–9.
- Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature*. 2013;496(7446):528–32.
- Westfall PJ, Pitera DJ, Lenihan JR, Eng D, Woolard FX, Regentin R, et al. Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. *Proc Natl Acad Sci U S A*. 2012;109(3): E111–8.
- Schempp FM, Drummond L, Buchhaupt M, Schrader J. Microbial cell factories for the production of terpenoid flavor and fragrance compounds. *J Agric Food Chem*. 2018;66(10):2247–58.
- Meadows AL, Hawkins KM, Tsegaye Y, Antipov E, Kim Y, Raetz L, et al. Rewriting yeast central carbon metabolism for industrial isoprenoid production. *Nature*. 2016;537(7622):694–7.
- McCarty NS, Ledesma-Amaro R. Synthetic biology tools to engineer microbial communities for biotechnology. *Trends Biotechnol*. 2019;37(2):181–97.
- Chen B, Lee HL, Heng YC, Chua N, Teo WS, Choi WJ, et al. Synthetic biology toolkits and applications in *Saccharomyces cerevisiae*. *Biotechnol Adv*. 2018;36(7):1870–81.
- Sun W, Xue H, Liu H, Yu Y, Wang Y, Huang M, et al. Controlling chemo- and regioselectivity of a plant p450 in yeast cell toward rare licorice triterpenoid biosynthesis. *ACS Catal*. 2020;10(7):4253–60.
- Dai Z, Liu Y, Sun Z, Wang D, Qu G, Ma X, et al. Identification of a novel cytochrome P450 enzyme that catalyzes the C-2a hydroxylation of pentacyclic triterpenoids and its application in yeast cell factories. *Metab Eng*. 2019;51:70–8.
- Wu T, Ye L, Zhao D, Li S, Li Q, Zhang B, et al. Membrane engineering—a novel strategy to enhance the production and accumulation of  $\beta$ -carotene in *Escherichia coli*. *Metab Eng*. 2017;43(Pt A):85–91.
- Sun ZJ, Lian JZ, Zhu L, Jiang YQ, Li GS, Xue HL, et al. Combined biosynthetic pathway engineering and storage pool expansion for high-level production of ergosterol in industrial *Saccharomyces cerevisiae*. *Front Bioeng Biotechnol*. 2021;9:681666.
- Delatte TL, Scaiola G, Molenaar J, de Sousa Farias K, Alves Gomes Albertti L, Busscher J, et al. Engineering storage capacity for volatile sesquiterpenes in *Nicotiana benthamiana* leaves. *Plant Biotechnol J*. 2018;16(12):1997–2006.

27. Wu S, Jiang Z, Kempinski C, Eric Nybo S, Husodo S, Williams R, et al. Engineering triterpene metabolism in tobacco. *Planta*. 2012;236(3):867–77.
28. Zhao C, Kim Y, Zeng Y, Li M, Wang X, Hu C, et al. Co-compartmentation of terpene biosynthesis and storage via synthetic droplet. *ACS Synth Biol*. 2018;7(3):774–81.
29. Read A, Schröder M. The unfolded protein response: an overview. *Biology*. 2021;10(5):384.
30. Hu Z, He B, Ma L, Sun Y, Niu Y, Zeng B. Recent advances in ergosterol biosynthesis and regulation mechanisms in *Saccharomyces cerevisiae*. *Indian J Microbiol*. 2017;57(3):270–7.
31. de Ruijter JC, Koskela EV, Frey AD. Enhancing antibody folding and secretion by tailoring the *Saccharomyces cerevisiae* endoplasmic reticulum. *Microb Cell Fact*. 2016;15:87.
32. Guerfal M, Claes K, Knittelfelder O, De Rycke R, Kohlwein SD, Callewaert N. Enhanced membrane protein expression by engineering increased intracellular membrane production. *Microb Cell Fact*. 2013;12:122.
33. Arendt P, Miettinen K, Pollier J, De Rycke R, Callewaert N, Goossens A. An endoplasmic reticulum-engineered yeast platform for overproduction of triterpenoids. *Metab Eng*. 2017;40:165–75.
34. Schuck S, Prinz WA, Thorn KS, Voss C, Walter P. Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response. *J Cell Biol*. 2009;187(4):525–36.
35. Kim JE, Jang IS, Son SH, Ko YJ, Cho BK, Kim SC, et al. Tailoring the *Saccharomyces cerevisiae* endoplasmic reticulum for functional assembly of terpene synthesis pathway. *Metab Eng*. 2019;56:50–9.
36. Milla P, Viola F, Oliaro Bosso S, Rocco F, Cattel L, Joubert BM, et al. Subcellular localization of oxidosqualene cyclases from *Arabidopsis thaliana*, *Trypanosoma cruzi*, and *Pneumocystis carinii* expressed in yeast. *Lipids*. 2002;37(37):1171–6.
37. Adeyo O, Horn PJ, Lee S, Binns DD, Chandras A, Chapman KD, et al. The yeast lipin orthologue Pah1p is important for biogenesis of lipid droplets. *J Cell Biol*. 2011;192(6):1043–55.
38. Guo XJ, Yao MD, Xiao WH, Wang Y, Zhao GR, Yuan YJ. Compartmentalized reconstitution of post-squalene pathway for 7-dehydrocholesterol overproduction in *Saccharomyces cerevisiae*. *Front Microbiol*. 2021;12:663973.
39. Gajdoš P, Ledesma-Amaro R, Nicaud JM, Čertík M, Rossignol T. Overexpression of diacylglycerol acyltransferase in *Yarrowia lipolytica* affects lipid body size, number and distribution. *FEMS Yeast Res*. 2016;16(6):1–8.
40. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. *Nat Rev Mol Cell Biol*. 2020;7(5):373–8.
41. Pateraki I, Andersen-Ranberg J, Hamberger B, Heskes AM, Martens HJ, Zerbe P, et al. Manoyl oxide (13R), the biosynthetic precursor of forskolin, is synthesized in specialized root cork cells in *Coleus forskohlii*. *Plant Physiol*. 2014;164(3):1222–36.
42. Muhammad A, Feng X, Rasool A, Sun W, Li C. Production of plant natural products through engineered *Yarrowia lipolytica*. *Biotechnol Adv*. 2020;43:07555.
43. Arhar S, Natter K. Common aspects in the engineering of yeasts for fatty acid- and isoprene-based products. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019;1864(12):158513.
44. Shi Y, Wang D, Li R, Huang L, Dai Z, Zhang X. Engineering yeast subcellular compartments for increased production of the lipophilic natural products ginsenosides. *Metab Eng*. 2021;67:104–11.
45. Gao Q, Binns DD, Kinch LN, Grishin NV, Ortiz N, Chen X, et al. Pet10p is a yeast perilipin that stabilizes lipid droplets and promotes their assembly. *J Cell Biol*. 2017;216(10):3199–217.
46. Wang D, Wang J, Shi Y, Li R, Fan F, Huang Y, et al. Elucidation of the complete biosynthetic pathway of the main triterpene glycosylation products of *Panax notoginseng* using a synthetic biology platform. *Metab Eng*. 2020;61:131–40.
47. Matthäus F, Ketelhot M, Gatter M, Barth G. Production of lycopene in the non-carotenoid-producing yeast *Yarrowia lipolytica*. *Appl Environ Microbiol*. 2014;80(5):1660–9.
48. Yu Y, Rasool A, Liu H, Lv B, Chang P, Song H, et al. Engineering *Saccharomyces cerevisiae* for high yield production of  $\alpha$ -amyrin via synergistic remodeling of  $\alpha$ -amyrin synthase and expanding the storage pool. *Metab Eng*. 2020;62:72–83.
49. Ma T, Shi B, Ye Z, Li X, Liu M, Chen Y, et al. Lipid engineering combined with systematic metabolic engineering of *Saccharomyces cerevisiae* for high-yield production of lycopene. *Metab Eng*. 2019;52:134–42.
50. Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. *Nat Rev Mol Cell Biol*. 2019;20(3):137–55.
51. Klug YA, Deme JC, Corey RA, Renne MF, Stansfeld PJ, Lea SM, et al. Mechanism of lipid droplet formation by the yeast Sei1/Ldb16 Seipin complex. *Nat Commun*. 2021;12(1):1–13.
52. Srinivasan P, Smolke CD. Engineering cellular metabolite transport for biosynthesis of computationally predicted tropane alkaloid derivatives in yeast. *Proc Natl Acad Sci USA*. 2021;118(25):e2104460118.
53. Tang WY, Wang DP, Tian Y, Fan X, Wang C, Lu XY, et al. Metabolic engineering of *Yarrowia lipolytica* for improving squalene production. *Bioresour Technol*. 2021;323:124652.
54. Wei LJ, Kwak S, Liu JJ, Lane S, Hua Q, Kweon DH, et al. Improved squalene production through increasing lipid contents in *Saccharomyces cerevisiae*. *Biotechnol Bioeng*. 2018;115(7):1793–800.
55. Joshi AS, Cohen S. Lipid droplet and peroxisome biogenesis: Do they go hand-in-hand? *Front Cell Dev Biol*. 2019;7:92.
56. Farré JC, Mahalingam SS, Proietto M, Subramani S. Peroxisome biogenesis, membrane contact sites, and quality control. *EMBO Rep*. 2019;20(1):e46864.
57. Tam YY, Torres-Guzman JC, Vizeacoumar FJ, Smith JJ, Marelli M, Aitchison JD, et al. Pex11-related proteins in peroxisome dynamics: a role for the novel peroxin Pex27p in controlling peroxisome size and number in *Saccharomyces cerevisiae*. *Mol Biol Cell*. 2003;14(10):4089–102.
58. Martín JF, Ullán RV, García-Estrada C. Role of peroxisomes in the biosynthesis and secretion of  $\beta$ -lactams and other secondary metabolites. *J Ind Microbiol Biotechnol*. 2012;39(3):367–82.
59. van der Klei IJ, Yurimoto H, Sakai Y, Veenhuis M. The significance of peroxisomes in methanol metabolism in methylotrophic yeast. *Biochim Biophys Acta*. 2006;1763(12):1453–62.
60. Zhou YJ, Buijs NA, Zhu Z, Gómez DO, Boonsombuti A, Siewers V, Nielsen J. Harnessing yeast peroxisomes for biosynthesis of fatty-acid-derived biofuels and chemicals with relieved side-pathway competition. *J Am Chem Soc*. 2016;138(47):15368–77.
61. Huttanus HM, HM X. Compartmentalized metabolic engineering for biochemical and biofuel production. *Biotechnol J*. 2017;12(6):1700052.
62. Kovacs WJ, Olivier LM, Krisans SK. Central role of peroxisomes in isoprenoid biosynthesis. *Prog Lipid Res*. 2002;41(5):369–91.
63. Liu GS, Li T, Zhou W, Jiang M, Tao XY, Liu M, et al. The yeast peroxisome: a dynamic storage depot and subcellular factory for squalene overproduction. *Metab Eng*. 2020;57:151–61.
64. Li Y, Zhao Z, Bai F. High-density cultivation of oleaginous yeast *Rhodospiridium toruloides* Y4 in fed-batch culture. *Enzyme Microb Technol*. 2007;41(3):312–17.
65. Ratledge C, Wynn JP. The biochemistry and molecular biology of lipid accumulation in oleaginous microorganisms. *Adv Appl Microbiol*. 2002;51:1–51.
66. Sibirny AA. Yeast peroxisomes: structure, functions and biotechnological opportunities. *FEMS Yeast Res*. 2016;16(4):1–14.
67. van der Klei IJ, Veenhuis M. Yeast peroxisomes: function and biogenesis of a versatile cell organelle. *Trends Microbiol*. 1997;5(12):502–9.
68. Saraya R, Veenhuis M, van der Klei IJ. Peroxisomes as dynamic organelles: peroxisome abundance in yeast. *FEBS J*. 2010;277(16):3279–88.
69. Yu H, Braun P, Yildirim MA, Lemmens I, Venkatesan K, Sahalie J, et al. High-quality binary protein interaction map of the yeast interactome network. *Science*. 2008;322(5898):104–10.
70. Tower RJ, Fagarasanu A, Aitchison JD, Rachubinski RA. The peroxin Pex34p functions with the Pex11 family of peroxisomal divisional proteins to regulate the peroxisome population in yeast. *Mol Biol Cell*. 2011;22(10):1727–38.
71. Motley AM, Nuttall JM, Hettema EH. Pex3-anchored Atg36 tags peroxisomes for degradation in *Saccharomyces cerevisiae*. *EMBO J*. 2012;31(13):2852–68.
72. Gerke J, Frauendorf H, Schneider D, Wintergoller M, Hofmeister T, Poehlein A, et al. Production of the fragrance geraniol in peroxisomes of a product-tolerant baker's yeast. *Front Bioeng Biotechnol*. 2020;8:582052.
73. Choi BH, Kang HJ, Kim SC, Lee PC. Organelle engineering in yeast: enhanced production of protopanaxadiol through manipulation of

- peroxisome proliferation in *Saccharomyces cerevisiae*. *Microorganisms*. 2022;10(3):650.
74. Bhataya A, Schmidt-Dannert C, Lee PC. Metabolic engineering of *Pichia pastoris* X-33 for lycopene production. *Process Biochem*. 2009;44(10):1095–102.
  75. Dusséaux S, Wajn WT, Liu Y, Ignea C, Kampranis SC. Transforming yeast peroxisomes into microfactories for the efficient production of high-value isoprenoids. *Proc Natl Acad Sci U S A*. 2020;117(50):31789–99.
  76. Zhang C, Li M, Zhao GR, Lu W. Harnessing yeast peroxisomes and cytosol acetyl-Coa for sesquiterpene  $\alpha$ -humulene production. *J Agric Food Chem*. 2020;68(5):1382–9.
  77. Guo Q, Shi TQ, Peng QQ, Sun XM, Ji XJ, Huang H. Harnessing *Yarrowia lipolytica* peroxisomes as a subcellular factory for  $\alpha$ -humulene overproduction. *J Agric Food Chem*. 2021;69(46):13831–7.
  78. Du MM, Zhu ZT, Zhang GG, Zhao YQ, Gao B, Tao XY, et al. Engineering *Saccharomyces cerevisiae* for hyperproduction of  $\beta$ -amyrin by mitigating the inhibition effect of squalene on  $\beta$ -amyrin synthase. *J Agric Food Chem*. 2022;70(1):229–37.
  79. Duran L, López JM, Avalos JL. ¡Viva la mitochondrial! harnessing yeast mitochondria for chemical production. *FEMS Yeast Res*. 2020;20(6):foaa037.
  80. Weinert BT, Iesmantavicius V, Moustafa T, Schözl C, Wagner SA, Magnes C, et al. Acetylation dynamics and stoichiometry in *Saccharomyces cerevisiae*. *Mol Syst Biol*. 2015;11(10):833.
  81. Zhu ZT, Du MM, Gao B, Tao XY, Zhao M, Ren YH, et al. Metabolic compartmentalization in yeast mitochondria: burden and solution for squalene overproduction. *Metab Eng*. 2021;68:232–45.
  82. Malwal SR, O'Dowd B, Feng X, Turhanen P, Shin C, Yao J, Bisphosphonate-generated ATP-analogs inhibit cell signaling pathways. *J Am Chem Soc*. 2018;140(24):7568–78.
  83. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, et al. A new endogenous ATP analog (Apppl) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. *Br J Pharmacol*. 2006;147(4):437–45.
  84. Farhi M, Marheвка E, Masci T, Marcos E, Eyal Y, Ovadis M, et al. Harnessing yeast subcellular compartments for the production of plant terpenoids. *Metab Eng*. 2011;13(5):474–81.
  85. Maarse AC, Van Loon AP, Riezman H, Gregor I, Schatz G, Grivell LA. Subunit IV of yeast cytochrome c oxidase: cloning and nucleotide sequencing of the gene and partial amino acid sequencing of the mature protein. *EMBO J*. 1984;3(12):2831.
  86. Yuan J, Ching CB. Mitochondrial acetyl-CoA utilization pathway for terpenoid productions. *Metab Eng*. 2016;38:303–9.
  87. Dong C, Shi Z, Huang L, Zhao H, Xu Z, Lian J. Cloning and characterization of a panel of mitochondrial targeting sequences for compartmentalization engineering in *Saccharomyces cerevisiae*. *Biotechnol Bioeng*. 2021;118(11):4269–77.
  88. Zhang Y, Wang J, Cao X, Liu W, Yu H, Ye L. High-level production of linalool by engineered *Saccharomyces cerevisiae* harboring dual mevalonate pathways in mitochondria and cytoplasm. *Enzyme Microb Technol*. 2020;134:109462.
  89. Yee DA, DeNicola AB, Billingsley JM, Creso JG, Subrahmanyam V, Tang Y. Engineered mitochondrial production of monoterpenes in *Saccharomyces cerevisiae*. *Metab Eng*. 2019;55:76–84.
  90. Tao XY, Lin YC, Wang FQ, Liu QH, Ma YS, Liu M, et al. Production of sesquiterpene patchoulol in mitochondrion-engineered *Saccharomyces cerevisiae*. *Biotechnol Lett*. 2022;44(4):571–80.
  91. Lv X, Wang F, Zhou P, Ye L, Xie W, Xu H, et al. Dual regulation of cytoplasmic and mitochondrial acetyl-CoA utilization for improved isoprene production in *Saccharomyces cerevisiae*. *Nat Commun*. 2016;7:12851.
  92. Yao Z, Zhou P, Su B, Su S, Ye L, Yu H. Enhanced isoprene production by reconstruction of metabolic balance between strengthened precursor supply and improved isoprene synthase in *Saccharomyces cerevisiae*. *ACS Synth Biol*. 2018;7(9):2308–16.
  93. Meng Y, Shao X, Wang Y, Li Y, Zheng X, Wei G, et al. Extension of cell membrane boosting squalene production in the engineered *Escherichia coli*. *Biotechnol Bioeng*. 2020;117:3499–507.
  94. Ye L, Zhu X, Wu T, Wang W, Zhao D, Bi C, et al. Optimizing the localization of astaxanthin enzymes for improved productivity. *Biotechnol Biofuels*. 2018;11:278.
  95. Werner N, Ramirez-Sarmiento CA, Agosin E. Protein engineering of carotenoid cleavage dioxygenases to optimize  $\beta$ -ionone biosynthesis in yeast cell factories. *Food Chem*. 2019;299:125089.
  96. Csáky Z, Garaiová M, Kodedová M, Valachovič M, Sychrová H, Hapala I. Squalene lipotoxicity in a lipid droplet-less yeast mutant is linked to plasma membrane dysfunction. *Yeast*. 2020;37(1):45–62.
  97. Liu P, Sun L, Sun Y, Shang F, Yan G. Decreased fluidity of cell membranes causes a metal ion deficiency in recombinant *Saccharomyces cerevisiae* producing carotenoids. *J Ind Microbiol Biotechnol*. 2016;43:525–35.
  98. Hong J, Park SH, Kim S, Kim SW, Hahn JS. Efficient production of lycopene in *Saccharomyces cerevisiae* by enzyme engineering and increasing membrane flexibility and NADPH production. *Appl Microbiol Biotechnol*. 2019;103(1):211–23.
  99. Zhang JL, Bai QY, Peng YZ, Fan J, Jin CC, Cao YX, et al. High production of triterpenoids in *Yarrowia lipolytica* through manipulation of lipid components. *Biotechnol Biofuels*. 2020;13:133.
  100. Nicolaou SA, Gaida SM, Papoutsakis ET. A comparative view of metabolite and substrate stress and tolerance in microbial bioprocessing: From biofuels and chemicals, to biocatalysis and bioremediation. *Metab Eng*. 2010;12:307–31.
  101. Fordjour E, Mensah EO, Hao Y, Yang Y, Liu X, Li Y, et al. Toward improved terpenoids biosynthesis: strategies to enhance the capabilities of cell factories. *Bioresour Bioprocess*. 2022;91(9):1–33.
  102. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. *Nature*. 2000;406(6797):775–81.
  103. Martínez JL, Sánchez MB, Martínez-Solano L, Hernandez A, Garmendia L, Fajardo A, et al. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. *FEMS Microbiol Rev*. 2009;33(2):430–49.
  104. Hara KY, Kobayashi J, Yamada R, Sasaki D, Kuriya Y, Hirono-Hara Y, et al. Transporter engineering in biomass utilization by yeast. *FEMS Yeast Res*. 2017. <https://doi.org/10.1093/femsyr/fox061>.
  105. Jungwirth H, Kuchler K. Yeast ABC transporters—a tale of sex, stress, drugs and aging. *FEBS Lett*. 2006;580(4):1131–8.
  106. Godinho CP, Costa R, Sá-Correia I. The ABC transporter Pdr18 is required for yeast thermotolerance due to its role in ergosterol transport and plasma membrane properties. *Environ Microbiol*. 2021;23(1):69–80.
  107. Claus S, Jezierska S, Van Bogaert INA. Protein-facilitated transport of hydrophobic molecules across the yeast plasma membrane. *FEBS Lett*. 2019;593(13):1508–27.
  108. Ro DK, Ouellet M, Paradise EM, Burd H, Eng D, Paddon CJ, et al. Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinin acid. *BMC Biotechnol*. 2008;8:83.
  109. Bi X, Guo N, Jin J, Liu J, Feng H, Shi J, et al. The global gene expression profile of the model fungus *Saccharomyces cerevisiae* induced by thymol. *J Appl Microbiol*. 2010;108(2):712–22.
  110. Hu F, Liu J, Du G, Hua Z, Zhou J, Chen J. Key cytomembrane ABC transporters of *Saccharomyces cerevisiae* fail to improve the tolerance to d-limonene. *Biotechnol Lett*. 2012;348(34):1505–9.
  111. Lee JJ, Chen L, Cao B, Chen WN. Engineering *Rhodospiridium toruloides* with a membrane transporter facilitates production and separation of carotenoids and lipids in a bi-phasic culture. *Appl Microbiol Biotechnol*. 2016;100(2):869–77.
  112. Bu X, Lin JY, Cheng J, Yang D, Duan CQ, Koffas M, et al. Engineering endogenous ABC transporter with improving ATP supply and membrane flexibility enhances the secretion of  $\beta$ -carotene in *Saccharomyces cerevisiae*. *Biotechnol Biofuels*. 2020;13:168.
  113. Wu T, Li S, Ye L, Zhao D, Fan F, Li Q, et al. Engineering an artificial membrane vesicle trafficking system (AMVTS) for the excretion of  $\beta$ -carotene in *Escherichia coli*. *ACS Synth Biol*. 2019;8(5):1037–46.
  114. Vasdekis AE, Silverman AM, Stephanopoulos G. Exploiting bioprocessing fluctuations to elicit the mechanistic of de novo lipogenesis in *Yarrowia lipolytica*. *PLoS ONE*. 2017;12(1):e0168889.
  115. Joshi AS, Nebenfuehr B, Choudhary V, Satpute-Krishnan P, Levine TP, Golden A, et al. Lipid droplet and peroxisome biogenesis occur at the same ER subdomains. *Nat Commun*. 2018;9(1):2940.
  116. Ast J, Stiebler AC, Freitag J, Bötker M. Dual targeting of peroxisomal proteins. *Front Physiol*. 2013;4:297.
  117. Ben-Menachem R, Pines O. Detection of dual targeting and dual function of mitochondrial proteins in yeast. *Methods Mol Biol*. 2017;1567:179–95.

118. Yogev O, Pines O. Dual targeting of mitochondrial proteins: mechanism, regulation and function. *Biochim Biophys Acta*. 2011;1808(3):1012–20.
119. Kumar V, Maity S. ER stress-sensor proteins and er-mitochondrial crosstalk-signaling beyond (ER) stress response. *Biomolecules*. 2021;11(2):173.
120. Zhou K, Qiao K, Edgar S, Stephanopoulos G. Distributing a metabolic pathway among a microbial consortium enhances production of natural products. *Nat Biotechnol*. 2015;33(4):377–83.
121. Wu S, Ma X, Zhou A, Valenzuela A, Zhou K, Li Y. Establishment of strigolactone-producing bacterium-yeast consortium. *Sci Adv*. 2021;7(38):eabh4048.
122. Hofmann S, Januliene D, Mehdipour AR, Thomas C, Stefan E, Brüchert S, et al. Conformation space of a heterodimeric ABC exporter under turnover conditions. *Nature*. 2019;571(7766):580–3.
123. Alkhadrawi AM, Xue H, Ahmad N, Akram M, Wang Y, Li C. Molecular study on the role of vacuolar transporters in glycyrrhethinic acid production in engineered *Saccharomyces cerevisiae*. *Biochim Biophys Acta Biomembr*. 2022;1864(6):183890.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

